Longs & Shorts from Sohn Sydney Conference
With all the political excitement last week, the first Sohn Sydney conference on 11th November does not appear to have received much airtime within...
515 Views
Current Share Price Ascribes No Value to Chronic Heart Failure Potential, but Risk Still Very High
We maintain our risk-adjusted DCF-based fair value estimate for Mesoblast of A$6 per share and reiterate our no-moat and very high uncertainty...
268 Views
Mesoblast's Partner Receives Full Approval in Japan; Commercial Launch Ahead
Mesoblast's Japanese partner, JCR Pharmaceuticals, has received full approval from the Japanese Ministry of Health, Labour and Welfare for its...
452 Views
Major Milestone Ahead for Mesoblast as Japanese Partner Moves Closer to Market with JR-031
Mesoblast's Japanese partner, JCR Pharmaceuticals, has announced that its acute Graft versus Host Disease, or aGvHD, product, JR-031, was...
395 Views